Evidence map›Paper›PMID 36755365›Full record

ArticleLupus science & medicine2022

Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE).

John Conklin, Michael Golpanian, Alexis Engel, Peter Izmirly, H Michael Belmont, Thierry Dervieux, Jill P Buyon, Roberta Vezza Alexander

Open access · goldAbstract read
In one paragraph

Article in Lupus science & medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. [Research progress on long-term developmental outcomes of offspring of pregnant women with systemic lupus erythematosus].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

John ConklinExagen Inc, Vista, California, USA.
Michael GolpanianDivision of Rheumatology, New York University School of Medicine, New York, New York, USA.
Alexis EngelDivision of Rheumatology, New York University School of Medicine, New York, New York, USA.
Peter IzmirlyDivision of Rheumatology, New York University School of Medicine, New York, New York, USA.
H Michael BelmontDivision of Rheumatology, New York University School of Medicine, New York, New York, USA.
Thierry DervieuxResearch and Development, Prometheus Laboratories, San Diego, California, USA.ORCID 0000-0002-3799-4438
Jill P BuyonDivision of Rheumatology, New York University School of Medicine, New York, New York, USA.ORCID 0000-0002-3852-7129
Roberta Vezza AlexanderExagen Inc, Vista, California, USA ralexander@exagen.com.ORCID 0000-0001-8827-8637
New York University · USPrometheus Biosciences (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundComplement activation has been associated with adverse pregnancy outcomes (APO) in SLE. Pregnant women with SLE were studied to evaluate whether complement dysregulation within the first two pregnancy trimesters predicts APO.

methodsPregnant women fulfilled classification criteria for SLE. APO included neonatal death, preterm delivery before 36 weeks and small for gestational age newborn. Pre-eclampsia was also evaluated. Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) were measured by flow cytometry. Complement proteins C3 and C4 were measured by immunoturbidimetry and anti-double-stranded DNA by ELISA in serum. Statistical analysis consisted of t-test, confusion matrix-derived diagnostic analysis, and multivariate logistic regression.

resultsFifty-one women had 57 pregnancies and 169 visits during the study. Baseline visits occurred mainly in the first (n=32) and second trimester (n=21). Fourteen (24.6%) pregnancies resulted in 21 APO with preterm delivery being the most common (n=10). ECR1 <5.5 net mean fluorescence intensity in the first trimester predicted APO with a diagnostic OR (DOR) of 18.33 (95% CI: 2.39 to 140.4; t-test p=0.04). Other individual biomarkers did not reach statistical significance. To estimate the likelihood of APO, we developed an algorithm that included the week of pregnancy, ECR1 and EC4d. From this algorithm, a Pregnancy Adversity Index (PAI) was calculated, and a PAI >0 indicated an elevated likelihood of pregnancy complications (DOR: 20.0 (95% CI: 3.64 to 109.97)).

conclusionsLow levels of ECR1 in early or mid-pregnancy are predictive of an APO. Incorporating the weeks of gestation and both ECR1 and EC4d generated a PAI, which further predicted serious pregnancy complications.

Indexed as

Lupus Erythematosus, SystemicPregnancy ComplicationsPremature BirthComplement C3ErythrocytesFemaleHumansInfant, NewbornPregnancyPregnancy OutcomeReceptors, ComplementComplement C3Receptors, Complementautoimmune diseasesautoimmunitylupus erythematosus, systemic

Identifiers

PMID36755365
PMCPMC9445792
OpenAlexW4294636761

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.